ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
NeuroSense Therapeutics Ltd

NeuroSense Therapeutics Ltd (NRSN)

0.7316
-0.0285
(-3.75%)
Closed July 19 4:00PM
0.7646
0.033
(4.51%)
After Hours: 7:57PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.7646
Bid
0.764
Ask
0.78
Volume
1,120,988
0.512 Day's Range 0.7911
0.40 52 Week Range 2.33
Previous Close
0.7601
Open
0.761
Last Trade
14
@
0.764
Last Trade Time
Average Volume (3m)
228,591
Financial Volume
$ 725,380
VWAP
0.64709

NRSN Latest News

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire CAMBRIDGE...

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as...

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., June 24, 2024 Following positive 6-month clinical outcomes from phase 2b...

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal PR Newswire CAMBRIDGE, Mass., June 21, 2024 CAMBRIDGE, Mass., June 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd...

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit PR Newswire CAMBRIDGE, Mass., May 20, 2024 CAMBRIDGE, Mass., May 20, 2024...

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning PR Newswire CAMBRIDGE, Mass., May 14, 2024 PhaseV's Causal Machine Learning Predicts...

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients PR...

NeuroSense Announces First Quarter 2024 Business Update

NeuroSense Announces First Quarter 2024 Business Update PR Newswire CAMBRIDGE, Mass., May 2, 2024 CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN...

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease PR Newswire CAMBRIDGE, Mass., April 22, 2024 CAMBRIDGE...

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting PR Newswire CAMBRIDGE, Mass., April...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2654-25.76699029131.031.050.5124027610.85821067CS
4-0.1322-14.74130240860.89681.50.5125074501.06969553CS
12-0.4754-38.33870967741.241.50.5122285911.09172768CS
26-0.1954-20.35416666670.962.330.5122663961.38969329CS
52-0.6554-46.15492957751.422.330.43654201.09666882CS
156-3.7854-83.19560439564.558.180.410924493.50517983CS
260-3.7854-83.19560439564.558.180.410924493.50517983CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.23M
AUGXAugmedix Inc
$ 2.27
(147.71%)
24.14M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.8M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.45k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.63M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
223.27k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.93M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
28.36M
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.23M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
226.79M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
217.1M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
188.2M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M

NRSN Discussion

View Posts
vein vein 1 week ago
Thanks much for the insight !
👍️0
runncoach runncoach 1 week ago
Who knows? Unless you are trading the stock, real results are a long ways off IMO and that can lead to opportunity cost. If it's a small percentage of a speculative portfolio the current price probably isn't bad. Just depends on your patience level
👍️0
vein vein 1 week ago
Why the sell off ?? Thanks in advance!
👍️0
vein vein 1 week ago
Seems like a decent entry ?
👍️0
runncoach runncoach 1 week ago
The data is good but they'll have to raise money for a P3 so these guys are still a ways off IMO. They've mentioned a potential Biogen partnership last year yet here we stand. I do believe the drug is safe and has a real chance. Timing is everything.
👍️0
vein vein 1 week ago
Time to buy now ??? Newbie here! Any thoughts ??
👍️0
Monksdream Monksdream 2 weeks ago
NRSN under $2
👍️0
runncoach runncoach 3 weeks ago
Great data out. On to P3. Only thing that will likely sustain share price after this rally is partnership IMO.
👍️0
Awl416 Awl416 3 weeks ago
Don’t blink
👍️0
runncoach runncoach 2 months ago
Certainly showing a positive trend on the scientific front.
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93791685/neurosense-announces-new-positive-data-analysis-fr
👍️0
runncoach runncoach 3 months ago
Financing broke the stock for now. Either Biogen news or dead money IMO
👍️0
runncoach runncoach 3 months ago
Looks like there will be a data presentation on the sixteenth at a conference. Back in for a gamble at 1.70.
👍️0
runncoach runncoach 3 months ago
And there's the money raise at 1.50
👍️0
runncoach runncoach 3 months ago
Sold at 2.12. Only update today on the additional biomarker data was talking about peer reviews and conferences. I expected data at least a month ago. I'm concerned they'll raise money before we get any significant data updates. I could be making a mistake but taking profits from .79 so can't be too upset if I do. I'll buy back if it goes lower most likely. GLTA
👍️0
glenn1919 glenn1919 4 months ago
NRSN..........................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 4 months ago
NRSN under $2
👍️0
runncoach runncoach 4 months ago
I like Coya a lot as well. I was hoping to see how the Biogen data plays out here and then moving funds there. Hopefully I'll get that chance. I'm not sure COYA's next coming data will be ideal based on the dosage and other trial parameters but could give a great indication to set up a pivotal P3. Lot of bigger money over there. I've got my eyes on them for sure. JMHO
👍️0
FooBarAndGrill FooBarAndGrill 4 months ago
Suggest a look at $COYA for ALS.
👍️0
runncoach runncoach 4 months ago
Disappointed for the ALS community. Hoping NRSN can provide some hope.
https://finance.yahoo.com/news/amylyx-pharmaceuticals-announces-topline-results-120000695.html?guccounter=1&guce_referrer=YW5kcm9pZC1hcHA6Ly9jb20uZ29vZ2xlLmFuZHJvaWQuZ29vZ2xlcXVpY2tzZWFyY2hib3gv&guce_referrer_sig=AQAAAAM8h3Ee_7hkwe__ixrWmntWVPdxe8WZ1ZpxVn7ZSc5Y_cvU8dUOeH8gNnkII0GDb_rsadt-ieRtojdTcEbDoBluMPdmwoVEaO7k8HMPi6OgMQhLipitwShkj668qEiwBreTeVNkxishXrsTPgOOOMTmvMybqLk3QVA9AiTxt2Bt
👍️0
runncoach runncoach 4 months ago
If Biogen results are good then yes. If not then no lol. It's a gamble. I'm not buying at these levels but my cost basis is .795 so I don't have to.
👍️0
BurgerKing82 BurgerKing82 4 months ago
Is it good time to buy ?
👍️0
Monksdream Monksdream 5 months ago
NRSN new 52 week high
👍️0
glenn1919 glenn1919 5 months ago
NRSN.................................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 months ago
NRSN........................................https://stockcharts.com/h-sc/ui?s=NRSN&p=W&b=5&g=0&id=p86431144783
👍️0
runncoach runncoach 5 months ago
I don't know about the biomarker data or any partnership discussions are going but this sure is a lot of volume in a positive fashion the last couple days.
👍️0
runncoach runncoach 5 months ago
Updated slide presentation fyi
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93337353/form-6-k-report-of-foreign-issuer-rules-13a-16
👍️0
runncoach runncoach 5 months ago
Looks like additional good news today but the neurofilament results we have been imminently expecting are on track for some time this quarter, which could mean another 5 or 6 weeks. The question remains of how good those results are (or aren't) and if the company raises money before or after. JMHO
👍️0
Awl416 Awl416 5 months ago
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
👍️0
Monksdream Monksdream 5 months ago
NRSN under $2
👍️0
BurgerKing82 BurgerKing82 5 months ago
Tues is the 20th I think....Any day.now?...tick tock....
👍️0
runncoach runncoach 5 months ago
Looks like the neurofilament light data in collaboration with Biogen isn't quite imminent as today's PR says the coming weeks fyi.
👍️0
runncoach runncoach 5 months ago
Looks like the company has regained full Nasdaq compliance
👍️0
BurgerKing82 BurgerKing82 5 months ago
Could be tomorrow lol
👍️0
runncoach runncoach 5 months ago
Not sure the holdup on the neurofilament light data. Though it was supposed to be out in January
👍️0
rouge Vaughn rouge Vaughn 6 months ago
yeah looking forward to 2 dollars and up with volume and news
👍️0
runncoach runncoach 6 months ago
Quite a run today. Fingers crossed on the new data when released
👍️0
runncoach runncoach 6 months ago
Only what you can afford to lose. As risky as any.
👍️0
BurgerKing82 BurgerKing82 6 months ago
How many shares do folks have in here...I was thinking of getting a few
👍️0
BurgerKing82 BurgerKing82 6 months ago
Sounds Rational...In 6/22 it did a little more than 3x on 220 million shares...In December it tripled on much smaller volume...Then again in 6/22 ,I guess it could have went a lot higher in pre- mkt/after-hours,maybe that kinda explains the huge volume....idk seems to have potential for a good rip
👍️0
runncoach runncoach 6 months ago
I don't honestly know. It's seen huge profit taking every time they've put out positive news. Traders/shorters, who knows. The company needs money to advance and when that's the case you see wild swings. The ball is in Biogen's court it would seem. All depends on the biomarker results we should get at any time.
👍️0
BurgerKing82 BurgerKing82 6 months ago
hey Runn....What caused Nrsn to dip.between Dec 4th-6th...just curious
👍️0
BurgerKing82 BurgerKing82 6 months ago
Supposedly they are fully funded into Q2 24'.....As of October 4....There was 22-26 million shares that went buy as the share price declined a bit in December...Maybe it's nothing..."We are optimistic about our mechanisms of action... anticipated in Q4 of 23'".......Still kinda interested


..
👍️0
BurgerKing82 BurgerKing82 6 months ago
This ticker looked pretty attractive until I noticed it was an Israeli one... Similar to Chinese, Israeli ones more often than not....Is it worth setting that factor aside?
👍️0
runncoach runncoach 6 months ago
Potentially yes as long as some of the biomarker data is good. We should find out about that data in the next week or two supposedly to the best of my understanding.
👍️0
BurgerKing82 BurgerKing82 6 months ago
Is there a positive Catalyst Coming later this month?
👍️0
rouge Vaughn rouge Vaughn 7 months ago
you choice is display picture is what is in question, here why are you using that image
👍️0
rakp rakp 7 months ago
Why this sudden reversal?
👍️0
Invest-in-America Invest-in-America 7 months ago
NRSN: How many time must I post this??? READ IT. I quoted the figures ACCURATELY. In any event, this JUNK STOCK is dead!! Let's all MOVE ON!!

https://www.google.com/search?q=is+als+a+rare+disease&sca_esv=588105669&source=hp&ei=an9vZdOZGevHkPIP2rCN8Aw&iflsig=AO6bgOgAAAAAZW-Nem49qIuR5YltejA1r0lBYMi_4ZKE&oq=is+als+a+ra&gs_lp=Egdnd3Mtd2l6IgtpcyBhbHMgYSByYSoCCAAyBRAAGIAEMgYQABgWGB4yCxAAGIAEGIoFGIYDMgsQABiABBiKBRiGA0iRL1AAWJ4YcAB4AJABAJgB0wKgAY4KqgEHNy4yLjEuMbgBAcgBAPgBAcICCxAAGIAEGLEDGIMBwgIOEC4YgAQYsQMYxwEY0QPCAgsQLhiABBjHARjRA8ICBRAuGIAEwgIREC4YgAQYsQMYgwEYxwEY0QPCAggQLhiABBixA8ICCBAAGIAEGLEDwgILEC4YxwEY0QMYgATCAg4QABiABBiKBRixAxiDAcICCxAuGIAEGLEDGIMBwgIXEC4YgAQYsQMYlwUY3AQY3gQY4ATYAQG6BgYIARABGBQ&sclient=gws-wiz
👍️0
runncoach runncoach 7 months ago
You were off somewhere between 30% and 600%. Do you know how much a patient pays a year for ALS medication? That would be quite a bit of difference in sales revenues. Either way potential sales, if ever, are quite a ways off no doubt. If Biogen takes over the indication would likely be much quicker through any approval process. JMHO
👍️0
cintrix cintrix 7 months ago
Do you need validation that bad? YOU stated it was EXTREMELY rare and I noted that I happen to know three people unrelated who got it so how EXTREMELY rare can that be? You want to get into semantics here? If I am a "moron" for stating a personal fact, then you are Infallible with a capital I.
👍️0